Key result
Dexmedetomidine is linked to ~71% lower in-hospital mortality in critically ill patients with AKI.
Why the study?
Dexmedetomidine's association with mortality and length of stay in critically ill patients was conflicting, and whether critically ill patients with acute kidney injury benefit from it was unknown.
Does dexmedetomidine administration reduce mortality and length of stay in critically ill patients with acute kidney injury?
Cohort (n=9,784)
No
Does dexmedetomidine administration reduce mortality and length of stay in critically ill patients with acute kidney injury?
Dexmedetomidine administration is associated with significantly reduced in-hospital and 90-day mortality in critically ill patients with mild to moderate acute kidney injury.
Answers are grounded in this paper and cite their sources.
Should not yet change dexmedetomidine use in critically ill AKI; leaves open a mortality benefit pending randomized confirmation.
Background Dexmedetomidine (DEX) had organ protection effects and could decrease mortality in animal models, but its association with mortality and length of stay (LOS) in ICU and hospital in critically ill patients was conflicting. Whether acute kidney injury (AKI) subgroup of critically ill patients could benefit from DEX was unknown. The present study aimed to evaluate the effects of DEX on clinical outcomes of critically ill patients with AKI. Methods Data were extracted from the Medical Information Mart for Intensive Care Ⅲ database (MIMIC Ⅲ). Propensity score matching (PSM) analysis (1:3), cox proportional hazards model, linear regression and logistic regression model were used to assess the effect of DEX on clinical outcomes. Results After PSM, 324 pairs of patients were matched between the patients with DEX administration and those without. DEX administration was associated with decreased in-hospital mortality [hazard ratio (HR) 0.287; 95% CI 0.151–0.542; P < 0.001] and 90-day mortality [HR 0.344; 95% CI 0.221–0.534; P < 0.001], and it was also associated with reduced length of stay (LOS) in ICU [4.54(3.13,7.72) versus 5.24(3.15,10.91), P < 0.001] and LOS in hospital [11.63(8.02,16.79) versus 12.09(7.83,20.44), P = 0.002]. Subgroup analysis showed the above associations existed only in mild and moderate AKI subgroups, but not in severe AKI subgroup. Nevertheless, DEX administration was not associated with the recovery of renal function [HR 1.199; 95% CI 0.851–1.688; P = 0.300]. Conclusions DEX administration improved outcomes in critically ill patients with mild and moderate AKI and could be a good choice of sedation.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2021) conducted a cohort in Acute kidney injury in critically ill patients (n=9,784). Dexmedetomidine vs. No dexmedetomidine was evaluated on In-hospital mortality (HR 0.287, 95% CI 0.151-0.542, p=<0.001). Dexmedetomidine administration was associated with a significant reduction in in-hospital mortality among critically ill patients with acute kidney injury.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: